Connect with us

Headlines

Bausch + Lomb Investment Sparks Good News for Valeant

mm

Published

on

New owner has invested $128 million in reorganization.

The $8.7 billion that Valeant Pharmaceuticals spent to purchase Bausch + Lomb Inc. last fall is apparently paying off. Even factoring in the $128 million the Montreal-based pharmaceuticals giant invested in a major overhaul of the B + L operation, Valeant reported record earnings for the quarter following the acquisition — $125 million, versus the previous year’s fourth quarter net loss of $89 million. Valeant’s sales for the fourth quarter of 2013 were $2.06 billion, more than double the $986 million it took in the same three months in 2012. Since Valeant’s takeover of the iconic eye care company, it has cut more than 400 positions at its manufacturing facilities in Rochester NY, and moved administrative headquarters from Rochester to New Jersey.

Read more at Rochester Democrat and Chronicle

SPONSORED VIDEO

Shamir Glacier Plus Metaform: Stronger. Thinner. Lighter.

It’s time for a new compromise-free lens technology that completely changes our concept of what's possible. Glacier Plus™ Metaform enables customers to enjoy strength and safety alongside the aesthetics of thin and light lenses. Now Available: The next technical revolution in the world of optics.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular